Establishment Labs Hldgs Inc - ESTA STOCK NEWS

Establishment Labs Holdings (NASDAQ: ESTA) is set to announce its financial results for Q4 2020 on March 10, 2021, before market open. A conference call will follow at 8:30 AM ET to discuss these results. The company specializes in women’s health, primarily in breast aesthetics, with its innovative Motiva Implants® and related technologies. Products are available in over 80 countries, adhering to strict regulatory standards. The company also initiated a clinical trial in the U.S. for Motiva Implants® after receiving FDA approval in March 2018.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós and CFO Renee Gaeta will attend the Cowen 41st Annual Healthcare Conference from March 1-4, 2021. They are scheduled to present on March 2, 2021, at 9:50 am ET. A live webcast of their presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women’s health, primarily in breast aesthetics and reconstruction, with products like Motiva Implants® available in over 80 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) hosted a virtual event on February 9, 2021, discussing its Motiva MIA system for minimally invasive breast augmentation. The MIA study shows reduced procedure time, lower post-operative pain, and quicker recovery compared to traditional methods. The company has expanded its clinical trials in Costa Rica and Thailand, aiming for regulatory approvals worldwide. Market research estimates a global market potential of $4-5 billion, indicating strong interest in the MIA system, with 50% of surveyed women willing to consider it over traditional surgery.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CEO Juan José Chacón-Quirós and CFO Renee Gaeta will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021. They are scheduled to present at 10:00 am ET on February 19. The conference offers a platform for discussions on the company's focus on women's health, particularly in breast aesthetics with their Motiva Implants®.

A live webcast and archived presentation will be accessible on their investor relations website.

Establishment Labs Holdings (NASDAQ: ESTA), a medical technology firm specializing in women’s health, announced a virtual investor event on Feb. 9, 2021, to discuss its innovative Motiva Mia® system. This system aims to provide a minimally invasive breast enhancement procedure with reduced recovery time and less pain compared to traditional methods. Renowned medical professionals will share insights from a recent clinical study involving 30 patients. Despite this advancement, the Motiva Mia system is not yet commercially approved. Registration for the event is available online.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will speak at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 4:30 PM ET. The conference will highlight the company's focus on women's health, particularly in breast aesthetics and reconstruction markets. A live webcast will be available for interested parties, with an archived version following the event. Establishment Labs is recognized for its Motiva Implants® and other innovative technologies, which are available in over 80 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced preliminary revenue figures for Q4 and FY 2020. Q4 revenue is expected between $26.5 million and $27.5 million, marking a 10% to 13% increase from $24.2 million in Q4 2019 and up to 20% from Q3 2020. FY 2020 revenue is projected at $84.2 million to $85.2 million, above prior guidance of $80 to $82 million. Cash reserves as of December 31, 2020, are anticipated to be around $84 million, up from $81.4 million in Q3 2020. The CEO highlighted effective contingency planning and market share gains as key contributors to this growth.

Establishment Labs Holdings (NASDAQ: ESTA) announced the receipt of a CE mark for its Motiva Ergonomix2 silicone breast implant platform, which includes the Motiva Ergonomix2 Diamond implant. This approval paves the way for the launch of the Motiva Mia minimally invasive augmentation system in Europe. The Ergonomix2 features advanced materials and patented technology aimed at enhancing patient comfort and minimizing complications. The company anticipates commencing pre-commercial procedures in Europe in the latter half of 2021, significantly shortening the approval timeline by three years.

Establishment Labs (NASDAQ: ESTA) has received Institutional Review Board (IRB) approval for its Motiva Mia system, which features the Ergonomix2 Diamond breast implant. The approval allows the company to initiate a patient series in Costa Rica, with the first procedures already completed on 21 patients. This innovative system aims for minimally invasive breast augmentation with quicker recovery times and less pain. The company is also set to conduct a separate patient series in Thailand, expected to begin in Q1 2021.